Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exercise, Spermidine, and Lamivudine or Rapamycin for Anti-Aging in Smokers
NCT07058974Phase 1Active, not recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Aug 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lamivudine and sirolimus in aging and inflammation (2 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoints: Number and Type of Grade 3/4 Adverse Events per CTCAE Version 5.0 at 180 days and Number of participants with ability to complete >80% of specified pharmacological intervention at 180 days. Started Aug 2025; status: active, not recruiting.
02
Drugs
lamivudinesirolimus
03
Conditions
aginginflammation
Beyond the preview
Go deeper on NCT07058974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07058974.